%0 Journal Article %1 Corrales:2016:J-Clin-Invest:27367184 %A Corrales, L %A McWhirter, S M %A Dubensky, T W %A Gajewski, T F %D 2016 %J J Clin Invest %K cancer-research fulltext immune-system immunology immunotherapy %N 7 %P 2404-2411 %R 10.1172/JCI86892 %T The host STING pathway at the interface of cancer and immunity %U https://www.ncbi.nlm.nih.gov/pubmed/27367184 %V 126 %X A major subset of human cancers shows evidence for spontaneous adaptive immunity, which is reflected by the presence of infiltrating CD8+ T cells specific for tumor antigens within the tumor microenvironment. This observation has raised the question of which innate immune sensing pathway might detect the presence of cancer and lead to a natural adaptive antitumor immune response in the absence of exogenous infectious pathogens. Evidence for a critical functional role for type I IFNs led to interrogation of candidate innate immune sensing pathways that might be triggered by tumor presence and induce type I IFN production. Such analyses have revealed a major role for the stimulator of IFN genes pathway (STING pathway), which senses cytosolic tumor-derived DNA within the cytosol of tumor-infiltrating DCs. Activation of this pathway is correlated with IFN-β production and induction of antitumor T cells. Based on the biology of this natural immune response, pharmacologic agonists of the STING pathway are being developed to augment and optimize STING activation as a cancer therapy. Intratumoral administration of STING agonists results in remarkable therapeutic activity in mouse models, and STING agonists are being carried forward into phase I clinical testing.

@article{Corrales:2016:J-Clin-Invest:27367184, abstract = {A major subset of human cancers shows evidence for spontaneous adaptive immunity, which is reflected by the presence of infiltrating CD8+ T cells specific for tumor antigens within the tumor microenvironment. This observation has raised the question of which innate immune sensing pathway might detect the presence of cancer and lead to a natural adaptive antitumor immune response in the absence of exogenous infectious pathogens. Evidence for a critical functional role for type I IFNs led to interrogation of candidate innate immune sensing pathways that might be triggered by tumor presence and induce type I IFN production. Such analyses have revealed a major role for the stimulator of IFN genes pathway (STING pathway), which senses cytosolic tumor-derived DNA within the cytosol of tumor-infiltrating DCs. Activation of this pathway is correlated with IFN-β production and induction of antitumor T cells. Based on the biology of this natural immune response, pharmacologic agonists of the STING pathway are being developed to augment and optimize STING activation as a cancer therapy. Intratumoral administration of STING agonists results in remarkable therapeutic activity in mouse models, and STING agonists are being carried forward into phase I clinical testing.}, added-at = {2019-04-24T23:07:33.000+0200}, author = {Corrales, L and McWhirter, S M and Dubensky, T W and Gajewski, T F}, biburl = {https://www.bibsonomy.org/bibtex/2390a608098178a47c5f069a7dffbc5ea/marcsaric}, description = {The host STING pathway at the interface of cancer and immunity. - PubMed - NCBI}, doi = {10.1172/JCI86892}, interhash = {c39aad80d07fbf3f9b3de00a7a621315}, intrahash = {390a608098178a47c5f069a7dffbc5ea}, journal = {J Clin Invest}, keywords = {cancer-research fulltext immune-system immunology immunotherapy}, month = {07}, number = 7, pages = {2404-2411}, pmid = {27367184}, timestamp = {2019-04-24T23:07:33.000+0200}, title = {The host STING pathway at the interface of cancer and immunity}, url = {https://www.ncbi.nlm.nih.gov/pubmed/27367184}, volume = 126, year = 2016 }